Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30 September 2023.

Highlights for the quarter included:

  • Clinical study agreement with MD Anderson Cancer Center for Phase 1B study of CHM 0201 in newly diagnosed Acute Myeloid Leukemia (AML)
  • Completion of CHM 1101 (CLTX CAR T) Phase 1A dose escalation in in recurrent/ progressive brain cancer
  • Positive in vitro data for CHM 0301
  • Patent allowance for chlorotoxin in Japan
  • Mr Eric Sullivan appointed to Board of Directors
  • US$3m introduction fee received 
For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?